Skip to main content
. 2023 May 31;136(15):1765–1782. doi: 10.1097/CM9.0000000000002536

Figure 2.

Figure 2

Current immunotherapy in NSCLC. Drawing tools: ScienceSlides (http://www.scienceslides.com/) and SMART (https://smart.servier.com/). CAR-T: Chimeric antigen receptor-modified T; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; NK: Natural killer; NSCLC: Non-small cell lung cancer; PD-1: Programed cell death protein 1; PD-L1: Programed cell death 1 ligand 1; TILs: Tumor-infiltrating lymphocytes.